MCRB
Seres Therapeutics, Inc.
Nasdaq · usd
Seres Therapeutics, Inc. (MCRB) trades at $1.40 (-1.06%) as of 11:23:06 AM EST on Nov 17, 2026, -41.52% over the past month. Market cap is $14.37M, with 4.3 days to cover in short interest.
Stock performance
How Seres Therapeutics, Inc. (MCRB) stock has performed from one day to one year, with its 52-week range.
- 1D
- +0.38%
- 1W
- -9.28%
- 1M
- -41.52%
- YTD
- -90.49%
- 1Y
- -94.27%
- 52-wk range
- $1.30 – $29.98
Key statistics
Today's trading snapshot for MCRB: day range, open, previous close, volume and market cap.
- Day range
- $1.33 – $1.50
- Open
- $1.39
- Prev close
- $1.41
- Volume
- 17.28K
- Market cap
- $14.37M
- Shares out
- 10.2M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Seres Therapeutics, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 6.76
- P/B
- 0.67
- P/FCF
- —
- ROE
- -219.8%
- ROA
- -71.3%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 16, 2026
8-K filings
Material corporate events Seres Therapeutics, Inc. has disclosed to the SEC on Form 8-K.
- Investor presentationNov 4, 2026
On November 4, 2026, the Company posted an updated corporate presentation (the "Corporate Presentation") to its website.
- Cfo departureOct 26, 2026
On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the "Company"), resigned from her positions as Executive Vice President and Chief Financial Officer of the Company, effective November 15, 2026 (the "Effective Date").
- Lease agreementAug 4, 2026
On July 31, 2026, Seres Therapeutics, Inc. entered into the Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC, the purpose of which is to effect an early termination of one of the Company's leases, reducing the Company's ongoing annual facilities costs and materially eliminating the Company's primary restoration obligations.
- Clinical trial resultsJul 8, 2026
On July 8, 2026, the Company announced top-line results from an IST evaluating SER-155 in patients with irEC. Following SER-155 dosing, 12 of 15 participants (80%) achieved an immunosuppressive-free clinical response at Day 15, the primary endpoint, defined as at least a 1-grade improvement in diarrhea symptoms without immunosuppressive therapy.
- Annual meeting resultsJul 8, 2026
On July 8, 2026, at the Annual Meeting, a total of 4,985,176 shares of the Company's common stock were represented in person or by proxy at the meeting, representing approximately 51.75% of the Company's outstanding Common Stock as of the April 13, 2026 record date. Based on the foregoing votes, the director nominees listed in Item 1 were elected and Items 2 through 5 were approved.
Dividend history and stock splits
Seres Therapeutics, Inc.'s recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-20Apr 22, 2025
MCRB short interest
How heavily MCRB is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 4.3
- Short interest
- 342.24K
- Avg volume
- 79.48K
As of · reported to FINRA twice monthly.
MCRB news
The latest news and headlines about Seres Therapeutics, Inc. (MCRB).
- Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026positiveGlobeNewswire Inc.· Oct 15, 2026
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)neutralGlobeNewswire Inc.· Sep 8, 2026
- Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026positiveGlobeNewswire Inc.· Apr 20, 2026
- Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesneutralGlobeNewswire Inc.· Mar 12, 2026
- $3.25+ Bn Human Microbiome Market Trends and Global Forecasts, 2035, Driven by Advancements in Microbiome Sequencing, Rising Investments in R&D, and Increasing Demand for Personalized MedicinepositiveGlobeNewswire Inc.· Feb 16, 2026
Frequently asked questions
What is the Seres Therapeutics, Inc. (MCRB) stock price today?
Seres Therapeutics, Inc. (MCRB) is trading at $1.40 (-1.06% on the day) as of 11:23:06 AM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Seres Therapeutics, Inc.?
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and…
What is the short interest in MCRB?
As of Oct 30, 2026, MCRB has 342.24K shares short and 4.3 days to cover.
What exchange is MCRB listed on?
Seres Therapeutics, Inc. (MCRB) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of MCRB with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a MCRB analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.